BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Moghimi SM, Simberg D, Papini E, Farhangrazi ZS. Complement activation by drug carriers and particulate pharmaceuticals: Principles, challenges and opportunities. Adv Drug Deliv Rev 2020;157:83-95. [PMID: 32389761 DOI: 10.1016/j.addr.2020.04.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Moghimi SM. Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines. Mol Ther 2021;29:898-900. [PMID: 33571463 DOI: 10.1016/j.ymthe.2021.01.030] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
2 Shi L, Zhang J, Zhao M, Tang S, Cheng X, Zhang W, Li W, Liu X, Peng H, Wang Q. Effects of polyethylene glycol on the surface of nanoparticles for targeted drug delivery. Nanoscale 2021;13:10748-64. [DOI: 10.1039/d1nr02065j] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
3 Kang Y, Liu J, Jiang Y, Yin S, Huang Z, Zhang Y, Wu J, Chen L, Shao L. Understanding the interactions between inorganic-based nanomaterials and biological membranes. Adv Drug Deliv Rev 2021;175:113820. [PMID: 34087327 DOI: 10.1016/j.addr.2021.05.030] [Reference Citation Analysis]
4 Li Y, Wang G, Griffin L, Banda NK, Saba LM, Groman EV, Scheinman R, Moghimi SM, Simberg D. Complement opsonization of nanoparticles: Differences between humans and preclinical species. J Control Release 2021;338:548-56. [PMID: 34481928 DOI: 10.1016/j.jconrel.2021.08.048] [Reference Citation Analysis]
5 Moghimi SM, Simberg D. Critical issues and pitfalls in serum and plasma handling for complement analysis in nanomedicine and bionanotechnology. Nano Today 2022;44:101479. [DOI: 10.1016/j.nantod.2022.101479] [Reference Citation Analysis]
6 Trzciński JW, Morillas-Becerril L, Scarpa S, Tannorella M, Muraca F, Rastrelli F, Castellani C, Fedrigo M, Angelini A, Tavano R, Papini E, Mancin F. Poly(lipoic acid)-Based Nanoparticles as Self-Organized, Biocompatible, and Corona-Free Nanovectors. Biomacromolecules 2021;22:467-80. [PMID: 33347750 DOI: 10.1021/acs.biomac.0c01321] [Reference Citation Analysis]
7 Ma Q, Pollard KM, Brown JM, Italiani P, Moghimi SM. Editorial: Immune Mechanisms in the Pathologic Response to Particles, Fibers, and Nanomaterials. Front Immunol 2021;12:665810. [PMID: 33815427 DOI: 10.3389/fimmu.2021.665810] [Reference Citation Analysis]
8 Wu LP, Ficker M, Christensen JB, Simberg D, Trohopoulos PN, Moghimi SM. Dendrimer end-terminal motif-dependent evasion of human complement and complement activation through IgM hitchhiking. Nat Commun 2021;12:4858. [PMID: 34381048 DOI: 10.1038/s41467-021-24960-6] [Reference Citation Analysis]
9 Xiao Q, Zhao W, Wu C, Wang X, Chen J, Shi X, Sha S, Li J, Liang X, Yang Y, Guo H, Wang Y, Fan JB. Lemon-Derived Extracellular Vesicles Nanodrugs Enable to Efficiently Overcome Cancer Multidrug Resistance by Endocytosis-Triggered Energy Dissipation and Energy Production Reduction. Adv Sci (Weinh) 2022;:e2105274. [PMID: 35187842 DOI: 10.1002/advs.202105274] [Reference Citation Analysis]
10 Yu Helvig S, Woythe L, Pham S, Bor G, Andersen H, Moein Moghimi S, Yaghmur A. A structurally diverse library of glycerol monooleate/oleic acid non-lamellar liquid crystalline nanodispersions stabilized with nonionic methoxypoly(ethylene glycol) (mPEG)-lipids showing variable complement activation properties. J Colloid Interface Sci 2021;582:906-17. [PMID: 32919118 DOI: 10.1016/j.jcis.2020.08.085] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
11 Decuzzi P, Peer D, Mascolo DD, Palange AL, Manghnani PN, Moghimi SM, Farhangrazi ZS, Howard KA, Rosenblum D, Liang T, Chen Z, Wang Z, Zhu JJ, Gu Z, Korin N, Letourneur D, Chauvierre C, van der Meel R, Kiessling F, Lammers T. Roadmap on nanomedicine. Nanotechnology 2021;32:012001. [PMID: 33043901 DOI: 10.1088/1361-6528/abaadb] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Tereshkina YA, Torkhovskaya TI, Tikhonova EG, Kostryukova LV, Sanzhakov MA, Korotkevich EI, Khudoklinova YY, Orlova NA, Kolesanova EF. Nanoliposomes as drug delivery systems: safety concerns. J Drug Target 2021;:1-13. [PMID: 34668814 DOI: 10.1080/1061186X.2021.1992630] [Reference Citation Analysis]
13 Brenner JS, Mitragotri S, Muzykantov VR. Red Blood Cell Hitchhiking: A Novel Approach for Vascular Delivery of Nanocarriers. Annu Rev Biomed Eng 2021;23:225-48. [PMID: 33788581 DOI: 10.1146/annurev-bioeng-121219-024239] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Onishchenko N, Tretiakova D, Vodovozova E. Spotlight on the protein corona of liposomes. Acta Biomater 2021:S1742-7061(21)00512-2. [PMID: 34364016 DOI: 10.1016/j.actbio.2021.07.074] [Reference Citation Analysis]
15 Viana IMO, Roussel S, Defrêne J, Lima EM, Barabé F, Bertrand N. Innate and adaptive immune responses toward nanomedicines. Acta Pharm Sin B 2021;11:852-70. [PMID: 33747756 DOI: 10.1016/j.apsb.2021.02.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
16 Münter R, Stavnsbjerg C, Christensen E, Thomsen ME, Stensballe A, Hansen AE, Parhamifar L, Kristensen K, Simonsen JB, Larsen JB, Andresen TL. Unravelling Heterogeneities in Complement and Antibody Opsonization of Individual Liposomes as a Function of Surface Architecture. Small. [DOI: 10.1002/smll.202106529] [Reference Citation Analysis]
17 Ashford MB, England RM, Akhtar N. Highway to Success—Developing Advanced Polymer Therapeutics. Adv Therap 2021;4:2000285. [DOI: 10.1002/adtp.202000285] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]